Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows: Date: September 23, 2026 Time: 1:30 PM ET The presentation will provide a detailed look at